Poverty and inequality in real-world schizophrenia: a national study

BackgroundSchizophrenia has high socioeconomic impact among severe psychiatric disorders.AimsTo explore clinician-reported and patient-reported inequities between patients under the poverty threshold vs. the others.Method916 patients consecutively recruited in 10 national centers received a comprehensive standardized evaluation of illness severity, addictions and patient-reported outcomes.Results739 (80.7%) of the patients were classified in the poverty group. This group had poorer objective illness outcomes (lower positive, negative, cognitive, excitement/aggressive and self-neglect symptoms and lifetime history of planned suicide) in multivariate analyses. While they had similar access to treatments and psychotherapy, they had lower access to socially useful activities, couple’s life, housing and parenthood. They had also more disturbed metabolic parameters. On the contrary, the poverty group reported better self-esteem. No significant difference for depression, risky health behavior including addictions and sedentary behavior was found.InterpretationThe equity in access to care is attributed to the French social system. However, mental and physical health remain poorer in these patients, and they still experience poor access to social roles independently of illness severity and despite healthcare interventions. These patients may have paradoxically better self-esteem due to decreased contact with society and therefore lower stigma exposure (especially at work). Schizophrenia presents itself as a distinct impoverished population concerning health-related outcomes and social integration, warranting focus in public health initiatives and improved treatment, including tailored interventions, collaborative care models, accessible mental health services, housing support, vocational training and employment support, community integration, education and awareness, research and data collection, culturally competent approaches, and long-term support

Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individuals

Background: The association between cannabis use and positive symptoms in schizophrenia spectrum disorders is well documented, especially via meta-analyses. Yet, findings are inconsistent regarding negative symptoms, while other dimensions such as disorganization, depression, and excitement, have not been investigated. In addition, meta-analyses use aggregated data discarding important confounding variables which is a source of bias. Methods: PubMed, ScienceDirect and PsycINFO were used to search for publications from inception to September 27, 2022. We contacted the authors of relevant studies to extract raw datasets and perform an Individual Participant Data meta-analysis (IPDMA). Inclusion criteria were: psychopathology of individuals with schizophrenia spectrum disorders assessed by the Positive and Negative Syndrome Scale (PANSS); cannabis-users had to either have a diagnosis of cannabis use disorder or use cannabis at least twice a week. The main outcomes were the PANSS subscores extracted via the 3-factor (positive, negative and general) and 5-factor (positive, negative, disorganization, depression, excitement) structures. Preregistration is accessible via Prospero: ID CRD42022329172. Findings: Among the 1149 identified studies, 65 were eligible and 21 datasets were shared, totaling 3677 IPD and 3053 complete cases. The adjusted multivariate analysis revealed that relative to non-use, cannabis use was associated with higher severity of positive dimension (3-factor: Adjusted Mean Difference, aMD = 0.34, 95% Confidence Interval, CI = [0.03; 0.66]; 5-factor: aMD = 0.38, 95% CI = [0.08; 0.63]), lower severity of negative dimension (3-factor: aMD = -0.49, 95% CI [-0.90; -0.09]; 5-factor: aMD = -0.50, 95% CI = [-0.91; -0.08]), higher severity of excitement dimension (aMD = 0.16, 95% CI = [0.03; 0.28]). No association was found between cannabis use and disorganization (aMD = -0.13, 95% CI = [-0.42; 0.17]) or depression (aMD = -0.14, 95% CI = [-0.34; 0.06]). Interpretation: No causal relationship can be inferred from the current results. The findings could be in favor of both a detrimental and beneficial effect of cannabis on positive and negative symptoms, respectively. Longitudinal designs are needed to understand the role of cannabis is this association. The reported effect sizes are small and CIs are wide, the interpretation of findings should be taken with caution

Handedness as a neurodevelopmental marker in schizophrenia: Results from the FACE-SZ cohort

Objectives: High rates of non-right-handedness (NRH) including mixed-handedness have been reported in neurodevelopmental disorders. In schizophrenia (SZ), atypical handedness has been inconsistently related to impaired features. We aimed to determine whether SZ subjects with NRH and mixed-handedness had poorer clinical and cognitive outcomes compared to their counterparts. Methods: 667 participants were tested with a battery of neuropsychological tests, and assessed for laterality using the Edinburg Handedness Inventory. Clinical symptomatology was assessed. Learning disorders and obstetrical complications were recorded. Biological parameters were explored. Results: The prevalence of NRH and mixed-handedness was high (respectively, 42.4% and 34.1%). In the multivariable analyses, NRH was associated with cannabis use disorder (p = 0.045). Mixed-handedness was associated with positive symptoms (p = 0.041), current depressive disorder (p = 0.005)), current cannabis use (p = 0.024) and less akathisia (p = 0.019). A history of learning disorder was associated with NRH. No association was found with cognition, trauma history, obstetrical complications, psychotic symptoms, peripheral inflammation. Conclusions: Non-right and mixed-handedness are very high in patients with SZ, possibly reflecting a neurodevelopmental origin. NRH is associated with learning disorders and cannabis use. Mixed-handedness is associated with positive symptoms, current depressive disorder, cannabis use and less akathisia. However, this study did not confirm greater cognitive impairment in these patients. © 2021 Informa UK Limited, trading as Taylor & Francis Group.Sorbonne Universités à Paris pour l'Enseignement et la RechercheFondaMental-Cohorte

Schizophrenia Bulletin Open

Treatment-resistant schizophrenia (TRS) affects around 30% of patients with schizophrenia (SZ) resulting in poor functioning, relapses, and reduced quality of life. Convergent findings show that inflammation could contribute to resistance. We thus search for immune signatures of patients with TRS/ultra TRS (UTRS) in a sample of community-dwelling outpatients with SZ. In total, 195 stabilized SZ patients (mean age = 31.2 years, 73% male gender) were consecutively included in the network of the FondaMental Expert Centers for Schizophrenia in France and received a thorough clinical assessment. At inclusion, psychotic symptomatology was evaluated by the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Circulating serum/plasma levels of a large panel of markers reflecting the main inflammatory pathways were evaluated. TRS was defined by current treatment by clozapine (CLZ) and UTRS by current CLZ treatment + PANSS total score ≥ 70. The frequency of TRS and UTRS patients was, respectively, 20% and 7.7% and was defined using multivariable analysis elevated by high levels of interleukin (IL)-12/IL-23p40, IL-17A, IL-10, and beta 2 microglobulin (B2M) and IL-12/IL-23p40, IL-17A, IL-6, IL-10, IFNγ, and B2M, respectively. These observations suggest that resistance and ultra resistance to CLZ treatment are underpinned by pro-inflammatory molecules mainly belonging to the T helper 17 pathway, a finding making sense given the interplay between inflammation and antipsychotic treatment responses. If confirmed, our findings may allow us to consider IL-23/IL-17 pathway as a therapeutic target for patients with resistance to antipsychotics.Sorbonne Universités à Paris pour l'Enseignement et la RechercheFondaMental-Cohorte

Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review

Progress in Neuropsychopharmacology & Biological Psychiatry 106 (2021) 110070 Jasmina Malleta,b,⁎, Caroline Dubertreta,b, Yann Le Strata,b a AP-HP, Department of Psychiatry, Louis Mourier Hospital, Université de Paris, Faculté de Médecine, Colombes, France b Institute of Psychiatry and Neurosciences of Paris (IPNP, Inserm U1266), 102 rue de la Santé, 75014 Paris, France Background: In the context of the COVID-19 worldwide pandemic, an up-to-date review of current challenges in addictions is necessary. While large scale disasters may have an impact on substance use and addictions, the use of some substances is also likely to modify the risk of COVID-19 infection or course. Many countries have imposed lockdowns. Whether this quarantine or the end of lockdown measures will have an impact on substance use is discussed. The aim of this review is to gather knowledge for clinicians and to guide public health policies during/after lockdown. Methods: PubMed was reviewed in August 6th (2020), to determine the current evidences and observations concerning the addictions and SARS-CoV2. We used all the names of the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV2 previously 2019 nCoV), the name of the coronavirus disease 2019 (COVID-19), and common substances of abuse. For the physiopathological parts, searches were conducted using key words such as “infection” or “pneumonia”. For the lockdown effects, key words such as “quarantine”, “disaster” or “outbreak” were used. Results: Overall, pathophysiological data showed an increased risk of infections for individuals with Substance Use Disorders (SUD) and a possible protective role of nicotine. During lockdown, there is a substantial risk of increasing SUDs. Individuals with opioid use disorder are particularly at risk of relapse or of involuntary withdrawal. After lockdown, increase of use may be observed as far as years after. Individuals with addictions are at higher risk of multimorbidity and mortality during COVID outbreak. Conclusion: This review describes useful strategies in clinical practice, including a systematic assessment of addiction comorbidity during this almost worldwide lockdown/pandemic. This review also highlights important areas for future research

Marqueurs neurodéveloppementaux, cognition et facteurs environnementaux précoces et tardifs dans le phénotype psychotique des pathologies mentales

Mental diseases represent a very heterogeneous categorical group, even within a given nosographic entity. Multifactorial approaches allow accounting for the clinical heterogeneity of mental disorders, the continuum between certain clinical dimensions, and even between the normal and the pathological. Among such dimensions, the psychotic phenotype constitutes an essential dimension of schizophrenic disorder. The dimensional approach allows for the search of psychotic experiences in most mental disorders as well as in the general population. We make the general hypothesis that certain psychiatric disorders with psychotic symptoms could be the result of the interaction between early- (obstetric traumas for example) and late- environmental factors (toxics, traumatisms) and the neurodevelopment of the individual. The initial step in this thesis work was to better define the concepts of vulnerability in psychiatry, and, based on the example of schizophrenia, to conduct a review of the literature on risk factors according to their early or late interaction with neurodevelopment. Subsequently, the first axis of research of the present thesis was to evaluate early neurodevelopmental markers (neurological soft signs, laterality, cognition). Our first work concerned the clinical, neurological and cognitive characterization of 64 patients suffering from schizophrenia, according to their cannabis use (or not) prior to psychosis. It provided evidence for a lower burden of neurodevelopment in cannabis users, and the potential impact of this substance on vulnerable individuals. Our second work concerns the clinical and cognitive impact of lateralization in patients with schizophrenia (n = 667) and bipolar disorder (n = 2445). We bring arguments for a neurodevelopmental weight (measured with this lateralization index) that is more important in schizophrenia. Our second axis of research focused on tobacco smoking as a late environmental factor in schizophrenia and psychotic phenotype. We showed in two studies on the FACE-SZ cohort (n = 361, n = 474) that SZ patients consumed almost twice as much as the general population and that they could represent a SZ subgroup with specific socio-demographic and clinical characteristics. In a third study, we compare the cognitive functions of these patients (n = 785) and show that the self-medication hypothesis alone cannot account for the high prevalence of their smoking. In a fourth work, we studied the impact of smoking on the psychotic phenotype with a dimensional approach, and showed an association between smoking and certain psychotic-type experiences in a representative sample of the US general population (NESARC, n = 34653). Finally, in a last line of research, we evaluated the psychotic phenotype in a population of adolescents and young adults hospitalized for a first psychiatric episode (n = 50). In a preliminary study, we show a high prevalence of psychotic-like experiences in these young adults, regardless of the diagnosis made six months afterwards, highlighting the trans-nosographic character of the psychotic phenotype during the emergence of different mental disorders. Overall, the present thesis underscores the clinical heterogeneity of mental illnesses and the importance of dimensional and trajectory approaches in identifying risk (or protective) factors, towards a better etiopathogenic understanding, better prevention opportunities, and a personalized patient care.Les maladies mentales représentent un ensemble catégoriel très hétérogène, même au sein d’une entité nosographique. L’approche multifactorielle rend compte de l’hétérogénéité clinique des troubles mentaux et du continuum entre certaines dimensions cliniques, voire entre le normal et le pathologique. Parmi ces dimensions, le phénotype psychotique constitue une dimension essentielle du trouble schizophrénique. L’approche dimensionnelle permet d’envisager la recherche d’expériences psychotiques dans la plupart des troubles mentaux ainsi qu’en population générale. Nous faisons l’hypothèse générale que certains troubles psychiatriques avec symptômes psychotiques pourraient être la résultante de l’interaction entre certains facteurs environnementaux précoces (traumatismes obstétricaux par exemple) et tardifs (consommation de toxiques, traumatismes) et le neurodéveloppement de l’individu. Un travail initial a été de rappeler les concepts de vulnérabilité en psychiatrie, et de prendre l’exemple du trouble schizophrénique pour réaliser une revue de la littérature sur les facteurs de risque en fonction de leur interaction précoce ou tardive avec le neurodéveloppement. Ensuite, dans le premier axe de recherche de la thèse, nous évaluons certains marqueurs neurodéveloppementaux précoces (signes neurologiques mineurs, latéralité, cognition). Notre premier travail, concerne la caractérisation clinique, neurologique et cognitive de 64 patients souffrant de trouble schizophrénique, en fonction de leur consommation de cannabis ou pas avant le début des troubles. Il apporte des éléments en faveur d’une charge neurodéveloppementale moins lourde chez les patients ayant consommé du cannabis, et de l’impact potentiel de cette substance chez des sujets vulnérables. Notre second travail, préliminaire, concerne l’impact clinique et cognitif de la latéralité chez les patients souffrant de schizophrénie (n=667) et de trouble bipolaire (n=2445). Nous apportons des arguments pour un poids neurodéveloppemental (mesuré avec cet indice) plus important dans la schizophrénie. Notre deuxième axe de recherche se concentre sur le tabagisme comme facteur environnemental tardif dans le trouble schizophrénique et le phénotype psychotique. Nous montrons dans deux travaux sur la cohorte FACE-SZ (n=361 ; n=474), que ces patients consomment presque deux fois plus qu’en population générale et qu’ils pourraient représenter un sous-groupe présentant des caractéristiques spécifiques d’un point de vue socio-démographique, clinique et thérapeutique. Dans un troisième travail préliminaire, nous comparons les fonctions cognitives de ces patients (n=785) et montrons que l’hypothèse d’automédication ne peut pas rendre compte à elle seule, de la forte prévalence du tabagisme chez ces patients. Dans un quatrième travail, nous étudions l’impact du tabagisme sur le phénotype psychotique dans une approche dimensionnelle, et montrons une association entre le tabagisme et certaines expériences de type psychotique dans un échantillon représentatif de la population générale américaine (NESARC, n=34653). Enfin dans un dernier axe de recherche nous nous intéressons au phénotype psychotique dans une population d’adolescents et jeunes adultes hospitalisés pour un premier épisode psychiatrique (n=50). Dans une étude préliminaire, nous montrons une forte prévalence des expériences de type psychotique chez ces jeunes adultes, quel que soit le diagnostic posé six mois à postériori, soulignant le caractère trans-nosographique du phénotype psychotique lors de l’émergence des troubles. L’ensemble de ce travail reflète l’hétérogénéité clinique des maladies mentales et l’importance de l’approche dimensionnelle et trajectorielle pour identifier des facteurs de risque (ou de protection). Les enjeux sont une meilleure compréhension étiopathogénique, des perspectives de prévention, et une prise en charge personnalisée des patients

Neurodevelopmental markers, cognition and early - and late- environmental factors in the psychotic phenotype of mental disorders

Les maladies mentales représentent un ensemble catégoriel très hétérogène, même au sein d’une entité nosographique. L’approche multifactorielle rend compte de l’hétérogénéité clinique des troubles mentaux et du continuum entre certaines dimensions cliniques, voire entre le normal et le pathologique. Parmi ces dimensions, le phénotype psychotique constitue une dimension essentielle du trouble schizophrénique. L’approche dimensionnelle permet d’envisager la recherche d’expériences psychotiques dans la plupart des troubles mentaux ainsi qu’en population générale. Nous faisons l’hypothèse générale que certains troubles psychiatriques avec symptômes psychotiques pourraient être la résultante de l’interaction entre certains facteurs environnementaux précoces (traumatismes obstétricaux par exemple) et tardifs (consommation de toxiques, traumatismes) et le neurodéveloppement de l’individu. Un travail initial a été de rappeler les concepts de vulnérabilité en psychiatrie, et de prendre l’exemple du trouble schizophrénique pour réaliser une revue de la littérature sur les facteurs de risque en fonction de leur interaction précoce ou tardive avec le neurodéveloppement. Ensuite, dans le premier axe de recherche de la thèse, nous évaluons certains marqueurs neurodéveloppementaux précoces (signes neurologiques mineurs, latéralité, cognition). Notre premier travail, concerne la caractérisation clinique, neurologique et cognitive de 64 patients souffrant de trouble schizophrénique, en fonction de leur consommation de cannabis ou pas avant le début des troubles. Il apporte des éléments en faveur d’une charge neurodéveloppementale moins lourde chez les patients ayant consommé du cannabis, et de l’impact potentiel de cette substance chez des sujets vulnérables. Notre second travail, préliminaire, concerne l’impact clinique et cognitif de la latéralité chez les patients souffrant de schizophrénie (n=667) et de trouble bipolaire (n=2445). Nous apportons des arguments pour un poids neurodéveloppemental (mesuré avec cet indice) plus important dans la schizophrénie. Notre deuxième axe de recherche se concentre sur le tabagisme comme facteur environnemental tardif dans le trouble schizophrénique et le phénotype psychotique. Nous montrons dans deux travaux sur la cohorte FACE-SZ (n=361 ; n=474), que ces patients consomment presque deux fois plus qu’en population générale et qu’ils pourraient représenter un sous-groupe présentant des caractéristiques spécifiques d’un point de vue socio-démographique, clinique et thérapeutique. Dans un troisième travail préliminaire, nous comparons les fonctions cognitives de ces patients (n=785) et montrons que l’hypothèse d’automédication ne peut pas rendre compte à elle seule, de la forte prévalence du tabagisme chez ces patients. Dans un quatrième travail, nous étudions l’impact du tabagisme sur le phénotype psychotique dans une approche dimensionnelle, et montrons une association entre le tabagisme et certaines expériences de type psychotique dans un échantillon représentatif de la population générale américaine (NESARC, n=34653). Enfin dans un dernier axe de recherche nous nous intéressons au phénotype psychotique dans une population d’adolescents et jeunes adultes hospitalisés pour un premier épisode psychiatrique (n=50). Dans une étude préliminaire, nous montrons une forte prévalence des expériences de type psychotique chez ces jeunes adultes, quel que soit le diagnostic posé six mois à postériori, soulignant le caractère trans-nosographique du phénotype psychotique lors de l’émergence des troubles. L’ensemble de ce travail reflète l’hétérogénéité clinique des maladies mentales et l’importance de l’approche dimensionnelle et trajectorielle pour identifier des facteurs de risque (ou de protection). Les enjeux sont une meilleure compréhension étiopathogénique, des perspectives de prévention, et une prise en charge personnalisée des patients.Mental diseases represent a very heterogeneous categorical group, even within a given nosographic entity. Multifactorial approaches allow accounting for the clinical heterogeneity of mental disorders, the continuum between certain clinical dimensions, and even between the normal and the pathological. Among such dimensions, the psychotic phenotype constitutes an essential dimension of schizophrenic disorder. The dimensional approach allows for the search of psychotic experiences in most mental disorders as well as in the general population. We make the general hypothesis that certain psychiatric disorders with psychotic symptoms could be the result of the interaction between early- (obstetric traumas for example) and late- environmental factors (toxics, traumatisms) and the neurodevelopment of the individual. The initial step in this thesis work was to better define the concepts of vulnerability in psychiatry, and, based on the example of schizophrenia, to conduct a review of the literature on risk factors according to their early or late interaction with neurodevelopment. Subsequently, the first axis of research of the present thesis was to evaluate early neurodevelopmental markers (neurological soft signs, laterality, cognition). Our first work concerned the clinical, neurological and cognitive characterization of 64 patients suffering from schizophrenia, according to their cannabis use (or not) prior to psychosis. It provided evidence for a lower burden of neurodevelopment in cannabis users, and the potential impact of this substance on vulnerable individuals. Our second work concerns the clinical and cognitive impact of lateralization in patients with schizophrenia (n = 667) and bipolar disorder (n = 2445). We bring arguments for a neurodevelopmental weight (measured with this lateralization index) that is more important in schizophrenia. Our second axis of research focused on tobacco smoking as a late environmental factor in schizophrenia and psychotic phenotype. We showed in two studies on the FACE-SZ cohort (n = 361, n = 474) that SZ patients consumed almost twice as much as the general population and that they could represent a SZ subgroup with specific socio-demographic and clinical characteristics. In a third study, we compare the cognitive functions of these patients (n = 785) and show that the self-medication hypothesis alone cannot account for the high prevalence of their smoking. In a fourth work, we studied the impact of smoking on the psychotic phenotype with a dimensional approach, and showed an association between smoking and certain psychotic-type experiences in a representative sample of the US general population (NESARC, n = 34653). Finally, in a last line of research, we evaluated the psychotic phenotype in a population of adolescents and young adults hospitalized for a first psychiatric episode (n = 50). In a preliminary study, we show a high prevalence of psychotic-like experiences in these young adults, regardless of the diagnosis made six months afterwards, highlighting the trans-nosographic character of the psychotic phenotype during the emergence of different mental disorders. Overall, the present thesis underscores the clinical heterogeneity of mental illnesses and the importance of dimensional and trajectory approaches in identifying risk (or protective) factors, towards a better etiopathogenic understanding, better prevention opportunities, and a personalized patient care

Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review

International audienceBackground: In the context of the COVID-19 worldwide pandemic, an up-to-date review of current challenges in addictions is necessary. While large scale disasters may have an impact on substance use and addictions, the use of some substances is also likely to modify the risk of COVID-19 infection or course. Many countries have imposed lockdowns. Whether this quarantine or the end of lockdown measures will have an impact on substance use is discussed. The aim of this review is to gather knowledge for clinicians and to guide public health policies during/after lockdownMethods: PubMed was reviewed in August 6th (2020), to determine the current evidences and observations concerning the addictions and SARS-CoV2. We used all the names of the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV2 previously 2019 nCoV), the name of the coronavirus disease 2019 (COVID-19), and common substances of abuse. For the physiopathological parts, searches were conducted using key words such as "infection" or "pneumonia". For the lockdown effects, key words such as "quarantine", "disaster" or "outbreak" were used.Results: Overall, pathophysiological data showed an increased risk of infections for individuals with Substance Use Disorders (SUD) and a possible protective role of nicotine. During lockdown, there is a substantial risk of increasing SUDs. Individuals with opioid use disorder are particularly at risk of relapse or of involuntary withdrawal. After lockdown, increase of use may be observed as far as years after. Individuals with addictions are at higher risk of multimorbidity and mortality during COVID outbreak.Conclusion: This review describes useful strategies in clinical practice, including a systematic assessment of addiction comorbidity during this almost worldwide lockdown/pandemic. This review also highlights important areas for future research

Patients’ awareness of recovery mediates the link between clinical and level of functional remission in schizophrenia to a larger extent in those treated with long-acting antipsychotics

Background: Clinical remission is a step towards functional remission for subjects with schizophrenia. While recovery is both a subjective personal journey and a clinical outcome to be targeted, data on patient self-rated outcomes are scarce. Objectives: (i) To determine the extent to which the association between clinical and functional remission is mediated by the subjective experience of recovery as reported by patients versus their relatives or their psychiatrist and (ii) to assess differences according to treatment, specifically with oral antipsychotics only versus long-acting injectable antipsychotics (LAIs). Design: Clinical observational study. Methods: Community-dwelling participants with schizophrenia enrolled in the EGOFORS cohort ( N  = 198) were included. Clinical symptoms and remission were assessed using the Positive and Negative Syndrome Scale. Functional remission was assessed with the Functional Remission of General Schizophrenia Scale. Awareness of recovery was assessed with one question ‘What percentage of recovery do you think you have now (from 0% – no recovery – to 100% – full recovery)?’, asked of the patient, also of the patient’s close relative, and the psychiatrist. We used mediation analyses, taking into account the type of pharmacological treatment. Results: Remission criteria and perceived remission measures were significantly correlated, both within and between groups ( r  > 0.330). The patient’s awareness of recovery mediated the relationship between clinical remission and level of functional remission, while the level of recovery according to psychiatrists or close relatives did not. The direct effect of clinical remission on the level of functional remission became non-significant when taking into account the mediator (patients’ awareness of recovery) in the group of patients with LAI ( t  = 1.5, p  = 0.150) but not in the group of patients with other treatments ( t  = 3.1, p  = 0.003). Conclusion: Patients with LAIs may be more efficient in reporting their level of functional remission. Higher patient awareness could be an interesting candidate to explain this. However, as the study was cross-sectional, such a proposal should be tested with a more specifically designed protocol, such as a long-term cohort

The COVID-19 Pandemic: Do Not Turn the Health Crisis Into a Humanity Crisis

International audienc